Hydrocortisone/Iodoquinol Shortage: What Providers and Prescribers Need to Know in 2026

Hydrocortisone/Iodoquinol has been a go-to dermatological compound for decades, particularly for conditions where inflammation and concurrent infection coexist — intertrigo, infected eczema, and chronic dermatoses. However, prescribing this medication in 2026 comes with practical challenges that every clinician should be aware of before sending a patient to the pharmacy.

FDA Regulatory Status: What Prescribers Must Understand

Hydrocortisone/Iodoquinol is marketed under FDA enforcement discretion as an unapproved drug. The FDA has not formally found it to be safe and effective, and its labeling has not undergone the standard NDA or ANDA approval process. The combination is described by the FDA/National Research Council as "possibly" effective for a range of dermatological conditions.

This regulatory gray zone has direct clinical and administrative implications: insurance plans routinely exclude it from formularies, and some pharmacy benefit managers flag it as a non-covered drug regardless of medical necessity. When prescribing, anticipate these barriers and counsel patients proactively.

Is There a National Shortage in 2026?

There is no FDA-declared shortage of Hydrocortisone/Iodoquinol as of 2026. Generic manufacturers (including Perrigo) continue to produce 1%/1% cream. The availability challenges your patients encounter are primarily demand-side: pharmacies have reduced stock of niche, poorly-reimbursed drugs. Branded versions (Alcortin A, Vytone) have a more complex history — some have undergone extreme price inflation followed by formulary exclusion, leading to de facto unavailability in many markets.

Insurance Coverage: What to Expect

The following insurance scenarios are common with Hydrocortisone/Iodoquinol prescriptions:

Commercial insurance: Most plans exclude branded products; generic 1%/1% may be covered on some formularies with prior authorization

Medicare Part D: Generally does not cover unapproved drugs; patients pay full cash price

Medicaid: Coverage varies significantly by state; prior auth often required

Prior authorization is frequently required for this drug on plans that do cover it. Medical necessity documentation should clearly articulate why this specific combination is required versus an FDA-approved alternative.

Clinical Considerations: Key Prescribing Pearls

Iodine allergy screening: Screen patients for iodine allergy or sensitivity to halogenated hydroxyquinolines before prescribing — contraindicated in these patients

Thyroid function tests: Advise patients not to undergo thyroid function tests until at least 1 month after discontinuation — iodoquinol can interfere

PKU testing: Iodoquinol can cause false-positive ferric chloride test for phenylketonuria

Pediatric caution: Safety and efficacy not established in children under 12; increased systemic absorption risk; not recommended per prescribing guidance

Staining: Iodoquinol stains skin, hair, and fabrics — counsel patients accordingly to prevent treatment non-adherence

Duration of use: Not recommended for prolonged use; risk of secondary infection with non-susceptible organisms

Preferred FDA-Approved Alternatives to Consider

If patient access to Hydrocortisone/Iodoquinol is consistently problematic, consider these FDA-approved alternatives:

Clotrimazole/betamethasone dipropionate (Lotrisone): FDA-approved, widely stocked, covered by most plans; note that betamethasone is medium-potency — avoid prolonged facial or intertriginous use

Nystatin/triamcinolone acetonide (Mycolog II): Excellent for cutaneous candidiasis and candidal intertrigo; generic available and low-cost

Separate components (ketoconazole + hydrocortisone): Flexible approach allowing independent titration of antifungal and anti-inflammatory components

How to Support Your Patients' Access

Direct patients who are having difficulty finding Hydrocortisone/Iodoquinol to medfinder for providers. medfinder calls pharmacies on the patient's behalf to check current inventory, helping avoid days of failed pharmacy calls. Providing patients with this resource at the point of prescribing can dramatically reduce the rate of unfilled prescriptions and patient callbacks.

For a practical workflow guide, see: How to Help Your Patients Find Hydrocortisone/Iodoquinol in Stock: A Provider's Guide.